2019 CYIR Finalized

32 were tested in the ARDS Network ARMA trial—so called “ultra- protective ventilation.” 2. Achievement of ultra-protective ventilation (tidal volume 3-4 cc/kg PBW, plateau pressure <25 cmH2O) may be limited by respiratory acidosis. 3. Extracorporeal carbon dioxide removal (ECCO2R) can facilitate ultra-protective ventilation in patients with moderate ARDS by minimizing respiratory acidosis; 82% of patients in this feasibil- ity study met ultra-protective targets using ECCO2R. 4. ECCO2R is associated with high rates of adverse events, including pneumothorax, bleeding and coagulopathies. 5. Additional investigations, including randomized clinical trials, are needed to determine if ultra-protective ventilation and ECCO2R improve outcomes for patients with ARDS. PEEP TITRATION IN MODERATE-SEVERE ARDS Beitler JR, Sarge T, Banner-Goodspeed VM, Gong MN, Cook D, Novack V, Loring SH, Talmor D, for the EPVent2 Study Group. Effect of Titrating Positive End-Expiratory Pressure (PEEP) With an Esophageal Pressure–Guided Strategy vs an Empirical High PEEP-FIO2 Strategy on Death and Days Free From Mechanical Ventilation Among Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial. JAMA 2019; 321(9) 846-857. Summary Titrating positive end-expiratory pressure (PEEP) to attempt to reduce atelectrauma may be hindered by inability to measure transpulmonary pressure (which requires mea- surement of pleural pressure) when relying on airway pressure alone. Pleural pressure can be estimated by measuring esophageal pressure. A single-center random- ized trial demonstrated that a strategy of PEEP titration using esophageal pressure improved oxygenation, respi- ratory system compliance, and adjusted survival. Beitler and colleagues at 14 hospitals randomized 200 patients with moderate-severe ARDS (PaO2:FIO2< 200 mmHg) to a strategy of esophageal pressure-guided PEEP titration or a high PEEP:FIO2 titration table (based on control group in OSCILLATE). The primary outcome was a ranked com- posite score that incorporated both death and days free of mechanical ventilation through day 28. Upon initiation of the study protocol, PEEP increased by a mean of 3 cmH2O in both groups, but the range of PEEP changes was much greater in the esophageal pressure-guided titration group (increased by up to 20 cmH2O and decreased by as much as 12 cm H2O). There was no difference in the primary end point between groups. Mortality at 28 days was around 31% in both groups, and there was no difference in ventila- tor free days. This study does not support routine use of esophageal pressure guided PEEP in ARDS. Comments 1. Ventilator induced lung injury has been shown to be dependent on transpulmonary pressure, which cannot be measured using airway pressure alone but can be estimated using esophageal pressure. 2. A previous single center randomized trial demonstrated benefit of a strategy of titrating PEEP using esophageal pressure when compared to a standard PEEP:FIO2 table. 3. EPVENT-2 randomized 200 patients at 14 hospitals to either an esophageal pressure-guided PEEP strategy or a high PEEP:FIO2 table-guided strategy. 4. There was no difference in primary outcome (ranked composite of mortality and days free of mechanical ventilation at 28 days) between study groups, or in physiologic outcomes. 5. There is likely no role for esophageal-pressure guided PEEP titration in routine management of patients with moderate- severe ARDS, especially if a high PEEP:FIO2 table is used. LOW TIDAL VOLUME VENTILATION IN PATIENTS WITHOUT ARDS Writing Group for the PReVENT Investigators. Effect of a Low vs Intermediate Tidal Volume Strategy on Ventilator-Free Days in Intensive Care Unit Patients Without ARDS: A Randomized Clinical Trial. JAMA 2018; 320(18): 1872-1880. Summary Low tidal volume ventilation improves survival in patients with ARDS, but the benefit of a lung protective strategy in patients without ARDS remains uncertain. At 6 hospitals in the Netherlands, the PReVENT investigators randomized patients expected to receive invasive ventilation for at least 24 hours to two ventilation strategies. Patients with ARDS were excluded, as were patients with significant hypoxemia (PaO2:FIO2 ratio < 200 mmHg) and ARDS risk factors. Both strategies allowed both volume control and pressure sup- port modes of ventilation. The lower tidal volume ventilation strategy targeted tidal volumes of 4 cc/kg PBW and allowed up to 6 cc/kg in the setting of severe dyspnea. The higher tidal volume ventilation strategy targeted tidal volumes of 10 cc/kg PBW and allowed down to 8 cc/kg in the setting of plateau pressure < 25 cm H2O. Patients who developed ARDS during the study were managed with conventional low tidal volume ventilation. The primary outcome measure was ventilator-free days and alive at day 28. There were 961 patients randomized, with median PaO2:FIO2 ratio of 196 at baseline. Most patients in the lower tidal volume strategy were managed with pressure support ventilation within 24 hours of randomization, with a median tidal volume of 7.8 cc/kg PBW (interquartile range 6.3-9.5). There was no dif- ference in ventilator free days, mortality, or development of ARDS between the strategies. Comments 1. The role of low tidal volume ventilation remains uncertain in patients with acute respiratory failure without ARDS, so the PReVENT study randomized patients without ARDS to two strategies that targeted lower (4 cc/kg PBW) and intermediate (10 cc/kg PBW) tidal volumes to address this knowledge gap. ARDS

RkJQdWJsaXNoZXIy MTM1ODMw